-
Local innovative pharmaceutical companies are ready to innovate and constantly break the monopoly of multinational pharmaceutical companies!
Time of Update: 2022-10-31
In recent years, national policies to encourage pharmaceutical innovation, such as volume procurement and medical insurance negotiation, have gradually advanced, in this context, local innovative drugs aim at the unmet clinical demand prospects of domestic patients, increase R&D investment, accumulate innovation, focus on the research and development of more new drugs, and constantly break the monopoly of multinational pharmaceutical companies, bringing good news to patients.
-
Under the tide of "slimming" in the pharmaceutical industry, the medical equipment manufacturer will lay off nearly 4,000 employees
Time of Update: 2022-10-31
On October 24, Philips, a Dutch medical device manufacturer, announced urgent actions to improve performance, including immediate layoffs of about 4,000 employees worldwide and an expected charge of about 300 million euros in the coming quarters.
-
Traditional Chinese medicine formula granules will open up a market of 100 billion yuan in the future, and this industry may follow the "light"
Time of Update: 2022-10-31
Formulated granules will open up a market of 100 billion It is understood that since November 2021, Chinese medicine formula granules have begun to switch to the new national standard, gradually upgrading to provincial standards and national standards, and this year has also been in the national standard switching period, but the implementation progress of traditional Chinese medicine formula granules in various places is different, resulting in different filing progress.
-
Dynamic analysis of Xi'an ferulic acid 98% fine powder rice bran extract supply industry
Time of Update: 2022-10-31
js?cdnversion='+~(-new Date()/36e5)]; Dynamic Analysis of Xi'an Ferulic Acid 98% Fine Powder Rice Bran Extract Supply Industry 1.
js?cdnversion='+~(-new Date()/36e5)]; Dynamic Analysis of Xi'an Ferulic Acid 98% Fine Powder Rice Bran Extract Supply Industry 1.
-
Chongqing Matjiang: Improve the service system of traditional Chinese medicine to make "minor diseases not leave home"
Time of Update: 2022-10-31
the Health Commissionmedicinal materials Wang Tao said in an interview with a reporter from China News Network that the next step will continue to promote Chinese medicine culture into campuses, communities, institutions, townships and enterprises, so that the cause of traditional Chinese medicine can be carried forward in inheritance and developed in innovation.
-
The selection of the ninth batch of excellent domestic medical equipment product catalogue was launched
Time of Update: 2022-10-31
Recently, the China Medical Equipment Association issued the "Announcement on Launching the Selection of the Ninth Batch of Excellent Domestic Medical Equipment Product Catalog". The ninth batch of e
-
Market analysis of water-soluble jujube extract Jujube polysaccharide 30%
Time of Update: 2022-10-31
Market analysis of water-soluble jujube extract Jujube polysaccharide 30% 1. Market analysis of water-soluble jujube extract Jujube polysaccharide 30% Product introduction 【Product Name】:Jujube extra
-
The sword refers to Merck Prevymis, Nanjing Chia Tai Tianqing Class 4 generic drug "Letemovir Tablets" reported production
Time of Update: 2022-10-31
Since 2017, Temovir tablets and intravenous formulations have been approved by the FDA for use in adult recipients of CMV-seropositive allogeneic hematopoietic stem cell transplantation (allo-HSCT) for the prevention of CMV infection, and the trade name is Prevymis.
-
The procurement of six major medical consumables is coming, and a large wave of consumables will usher in price reductions
Time of Update: 2022-10-31
According to the announcement, the estimated procurement quantity of this volume procurement project is estimated according to 70% of the estimated total procurement of public medical institutions in Taiyuan, Jinzhong, Xinzhou and Luliang.
-
The road to the rise of China's innovative drugs: too much Lilly, too few Novo Nordisks
Time of Update: 2022-10-31
/ 03 / China's innovative pharmaceutical companies also need more ingenuity Lilly's model is worth learning, and Novo Nordisk's model can also be learned.
/ 03 / China's innovative pharmaceutical companies also need more ingenuity Lilly's model is worth learning, and Novo Nordisk's model can also be learned.
-
Mindray, WuXi and Hengrui set off a "buyback wave"! Multi-dimensional "bottoming" boost
Time of Update: 2022-10-25
According to incomplete statistics from the New Media Center of "Medical Economic News", in the past month, WuXi Biologics has been active in repurchases, with a total of nearly 1 billion Hong Kong dollars invested in eight repurchase executions and more than 20 million shares repurchased (data as of the close of the market on October 14).
-
The end of 2022 is approaching, and pharmaceutical executives are leaving!
Time of Update: 2022-10-25
On October 10, Hengrui Pharmaceutical announced that the company's board of directors recently received a resignation report from Tao Weikang, deputy general manager of the company, and after resigning from the above position due to personal reasons, Tao Weikang will no longer hold any position in the company.
-
Exposure! Another batch of pharmaceutical companies were fined for producing and selling counterfeit drugs
Time of Update: 2022-10-25
According to the penalty documents, the parties purchased a total of 15kg of the above-mentioned madder from a company in Yunnan on September 2, 2021, January 24, April 27, and May 11, 2022, with a unit price of 316.
-
Novartis, Abbott, Sanofi, Merck split generic drug apocalypse!
Time of Update: 2022-10-25
Looking at the entire generic drug industry, it has been infinitely prosperous: large companies continue to buy, mergers and acquisitions and expand, are sought after by capital and leverage, and have also ushered in a surge in stock price market value; Nowadays, many products and documents are changed or discontinued through subtraction, divestiture and sale.
-
Chinese pharmaceutical companies are frequently acquiring overseas companies to accelerate internationalization
Time of Update: 2022-10-25
Therefore, for pharmaceutical companies initiating mergers and acquisitions, choosing to acquire small pharmaceutical companies with R&D and production capabilities can quickly expand their product lines and cut into new fields.
-
The market potential of proprietary Chinese medicine gastric medicine is huge, which has attracted many pharmaceutical companies to make efforts to grab food
Time of Update: 2022-10-25
Qingfeng Pharmaceutical is also actively deploying in the Chinese proprietary medicine gastric medicine market, and has won the production approval of monkey mushroom drink oral liquid, and Ollantic Gastro Kang tablets are expected to become the company's first Class 1 new drug in this field.
-
The NMPA approved the registration of 222 medical device product announcements
Time of Update: 2022-10-25
, Ltd The national weapon is 20223221181 The national weapon is 20223221181 41 Single-use endovascular imaging catheters Tianjin Hengyu Medical Technology Co.
, Ltd The national weapon is 20223401239 The national weapon is 20223401239 99 Novel Coronavirus (2019-nCoV) Nucleic Acid Detection Kit (Fluorescent PCR Method) Shenzhen Taylor Medical Co.
-
Hereditary angioedema (HAE) new drug! Takhzyro (rana lu monoclonal antib) received priority review by the US FDA: treatment of pediatric patients aged 2-12 years!
Time of Update: 2022-10-25
Food and Drug Administration Accepts Takeda's Supplemental Biologics License Application for Use of TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older Takhzyro is the first monoclonal antibody drug for the treatment of HAE, which specifically binds to and inhibits the activity of plasma kallikrein enzyme.
-
Analysis and revision of GMP deficiency in China in 2010
Time of Update: 2022-10-25
There is no doubt that China's GMP (2010 Revision), which came into effect on March 1, 2011, has played a key role in standardizing the business practices of Chinese pharmaceutical companies, promoti
-
With a drug market of nearly 30 billion, a large number of domestic pharmaceutical companies are competing for layout
Time of Update: 2022-10-25
js?cdnversion='+~(-new Date()/36e5)]; Recently, GlaxoSmithKline (GSK) announced that the expanded study of its recombinant herpes zoster vaccine "Xin'anlishi" has achieved positive interim results.
js?cdnversion='+~(-new Date()/36e5)]; Recently, GlaxoSmithKline (GSK) announced that the expanded study of its recombinant herpes zoster vaccine "Xin'anlishi" has achieved positive interim results.
